louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03936530: Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
Official title: Infrapyloric (No.206) and Greater Curvature (No.204) Lymph Node Metastasis in Adenocarcinoma Located at Hepatic Flexure and Right Half of Transverse Colon
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Colorectal Neoplasm
Keywords: colon adenocarcinoma
lymph node metastasis
right hemi-colectomy
Lead sponsor: Shanghai Minimally Invasive Surgery Center
Sponsor class: OTHER
First posted: 2019-05-03
Enrollment: 432
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in Shanghai Minimally Invasive Surgery Center

Brief summary: The infrapyloric (No.206) and greater curvature (No.204) lymph node metastasis in adenocarcinoma located at hepatic flexure and right half of transverse colon has not been well discribed and analysed. The aim of this study is to assess the rate of this lymph node metastasis and to reveal its prognostic value for colon cancer located at hepatic flexure and right half of transverse colon. Meanwhile, we can evaluate the safety and feasibility of this extented lymphadenectomy in right hemi-colectomy.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 75 years
* American Society of Anesthesiologists (ASA) score I to III
* A biopsy proven histological diagnosis of colorectal carcinoma
* tumor located at hepatic flexure and right half of transverse colon
* Undergoing right hemi-colectomy with extented lymphadenectomy of infrapyloric (No.206) and greater curvature (No.204) lymph node
* Preoperative staging cT2-4aN0M0 or cTanyN+M0
* Willing to participate and informed consent signed

Exclusion Criteria:

* Pregnant or lactating women
* Synchronous colorectal carcinoma
* History of colorectal cancer or other malignant tumors
* Clinical evidence of metastasis
* Preoperative staging cT1N0 or cT4bNany
* Emergency procedure

Primary outcomes:
measure: metastasis rate
timeFrame: an average of 1 year
Secondary outcomes:
measure: lymphadenectomy time
timeFrame: an average of 1 year
measure: intraoperative complication
timeFrame: an average of 1 year
measure: postoperative complication
timeFrame: an average of 1 year
measure: 3-year DFS
timeFrame: an average of 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT02185430: Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD, One Lung Ventilation
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-07-09
Enrollment: 63
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: COPD is often associated with the airflow limitation and the pulmonary hyperinflation. During the one-lung ventilation (OLV), COPD patients' physiologic dead space increases and hypercapnia may develop. In addition, an alveolar overdistention by the pulmonary hyperinflation would divert pulmonary blood flow and impair arterial oxygenation. Dexmedetomidine has both vasoconstricting and vasodilatatory effects on a peripheral vasculature and a smooth muscle but its effects on bronchial smooth muscle is unknown. The investigators will evaluate the effects of dexmedetomidine (bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation) as bronchodilator in COPD patients when administered during surgery with the one lung ventilation. If result successfully shows the effect of dexmedetomidine as a predominantly a vasodilator on bronchial tree, the investigators study can support the dexmedetomidine as a vasodilator for pulmonary vessels and bronchial smooth muscle and as an excellent adjunct to anesthetic agents in COPD patients during the OLV.


Eligibility criteria: Inclusion Criteria:

1. Above 40 years of age
2. American Society of Anesthesiologists (ASA) Physical Status I, II, III.
3. COPD diagnosed , criteria ( on preop. PFT : FEV1 \< 80%, FEV1 / FVC \< 70% after bronchodilator)
4. thoracic surgical procedure

Exclusion Criteria:

1. severe functional liver or kidney disease
2. diagnosed HF ( NYHA class \>3)
3. arrhythmia or received treatment with antiarrythmic drug .
4. exceed BMI \> 30 kg/ m2
5. bradycardia (HR \<50 bpm)

Primary outcomes:
measure: The change of the oxygenation
timeFrame: At two-lung ventilation (T1) , 20 min after of one-lung ventilation (T2), 30 mins after Dex or placebo saline infusion (T3), 60 mins after Dex or placebo saline infusion (T4), at the termination of surgery in TLV (T5)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine
name: Young Jun Oh, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee SH, Kim N, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A randomised double-blinded trial. Eur J Anaesthesiol. 2016 Apr;33(4):275-82. doi: 10.1097/EJA.0000000000000405.
Clinical trial NCT01726530: Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial
Official title: Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain Relief
Keywords: transdermal fentanyl patch, postoperative pain,
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2012-11-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Abdominal surgery causes severe postoperative pain. Multi-modal pain therapy is usually applied but there is no perfect choice. It depends on physician's skill and situation. The best regimen is patient-controlled analgesia, but it requires an expensive equipment. Transdermal fentanyl patch, usually used in chronic pain relief, can steadily release fentanyl into blood stream for 72 hours, but it has slow onset of 12 hours.

Hypothesis: If Transdermal fentanyl patch is applied 10-12 hours before surgery, it may provide good analgesia for 72 hours.


Eligibility criteria: Inclusion Criteria:

* age =\>18 years
* scheduled for abdominal surgery

Exclusion Criteria:

* ASA class \> 3
* Known allergy to fentanyl or morphine
* History of substance or alcohol abuse, and tolerance or dependence on opioids
* Combined epidural block
* Can't use PCA, abnormal renal / liver function

Primary outcomes:
measure: morphine consumption
timeFrame: 24 hours
Secondary outcomes:
measure: morphine consumption
timeFrame: 48 and 72 hours
Other outcomes:
measure: side effects
timeFrame: 72 hours
Locations:
city: Khon Kaen
country: Thailand
facility: Srinagarind hospital
Study officials:
affiliation: Khon Kaen University
name: Thepakorn Sathitkarnmanee, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT04949230: A Retrospective Study of COVID-19 Treatments
Official title: A Retrospective Study to Analyze Efficacy of COVID-19 Treatments
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Bronchitis
COVID-19 Acute Respiratory Distress Syndrome
COVID-19 Lower Respiratory Infection
SARS-CoV2 Infection
SARS-CoV-2 Acute Respiratory Disease
Lead sponsor: ProgenaBiome
Sponsor class: OTHER
First posted: 2021-07-02
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 1. Refusal to sign informed consent form

Brief summary: Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

Detailed description: Subjects who have recovered from COVID-19 will answer questions regarding the severity of their illness, symptoms experienced, what treatment they received, and how long they were ill.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
2. Male or female of 18 years of age or older
3. Diagnosis of COVID-19 infection by RT- PCR
4. Recovery from COVID-19

Exclusion Criteria:

Primary outcomes:
measure: Survey Response
timeFrame: One hour
Secondary outcomes:
Other outcomes:
Locations:
city: Ventura
country: United States
facility: Ginger Aurella
state: California
Study officials:
affiliation: ProgenaBiome
name: Sabine Hazan, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02606630: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
Official title: A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Multiple Sclerosis
Keywords: Relapsing multiple sclerosis
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2015-11-17
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This open-label positron emission tomography (PET) study is designed to determine the effect of ABT-555 on translocator protein expression level in participants with relapsing forms of multiple sclerosis.


Eligibility criteria: Inclusion Criteria:

Diagnosis of relapsing-remitting MS (RRMS) or relapsing secondary progressive MS (SPMS)

Neurologically stable at Screening, in the investigator's judgment and not actively experiencing or recovering from a recent relapse in the 30 days preceding the Screening Visit

A Kurtzke Expanded Disability Status Scale (EDSS) score of 1.0 to 6.0, inclusive at the Screening Visit

High or mixed affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at screening

Exclusion Criteria:

Diagnosis of primary progressive or non-relapsing secondary progressive MS

Smoking more than 10 cigarettes per day or use of a nicotine patch

Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus

Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening

Any type of live virus vaccine from 4 weeks before randomization

History of abnormal laboratory results

Primary outcomes:
measure: Change in translocator protein expression
timeFrame: Day 0 and 109 days
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Site Reference ID/Investigator# 141463
city: Whitechapel
country: United Kingdom
facility: Site Reference ID/Investigator# 141461
Study officials:
affiliation: AbbVie
name: Steven Greenberg, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02260830: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
Official title: Interventional, Open-label, Part Fixed Sequence, Part-randomised Study Investigating the Pharmacokinetic Properties of up to 6 Prototype Modified Release Tablet Formulations of Lu AF11167 in Healthy Young Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Schizophrenia
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2014-10-09
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the pharmacokinetic (PK) properties of various modified release tablet formulations of Lu AF11167 (Part A) and to investigate the pharmacokinetic (PK) properties of a modified release tablet formulation of Lu AF11167 in a fed and fasted state and following multiple dosing (Part B).


Eligibility criteria: Inclusion Criteria:

* Healthy men and women ≥18 and ≤45 years of age with a body mass index (BMI) of \>18.5 and \<30.0 kg/m2.
* Women of child-bearing potential will have a confirmed non-pregnant and non-lactating status.
* Other pre-defined inclusion and exclusion criteria may apply.

Primary outcomes:
measure: PK parameters for Lu AF11167 estimated from the single dose treatment periods in Part A and B: Cmax, Frel, AUC0-inf, AUC0t, AUC%extr, CL/F, t½, tlag, tmax and Vz/F.
timeFrame: 0-48 hours
measure: PK parameters for Lu AF11167 estimated from the multiple dose treatment period in Part B: AUC0-tau, AI (accumulation index), Cmax, Cpre, CL/F, t½, tmax and Vz/F.
timeFrame: Up to 60 hours post dose on day 7
Secondary outcomes:
measure: PK parameters for Lu AF36201 estimated from the single dose treatment periods in Part A and B: Cmax, AUC0-inf, AUC0-t, AUC%extr, t½, tlag and tmax, MR (metabolic ratio).
timeFrame: 0-48 HOurs
measure: PK parameters for Lu AF36201 estimated from the multiple dose treatment period in Part B: AUC0-tau, AI, Cmax, Cpre, MR, t½ and tmax.
timeFrame: Up to 60 hours post dose day 7
Other outcomes:
measure: Number of adverse events
timeFrame: Up to 70 days
Locations:
city: Nottingham
country: United Kingdom
facility: Quotient Clinical
Study officials:
affiliation: LundbeckClinicalTrials@lundbeck.com
name: Email contact via LundbeckClinicalTrials@Lundbeck.com
role: STUDY_DIRECTOR
References:
Clinical trial NCT01172730: The Use of Ultrasound to Measure Depth of Thoracic Epidural Space
Official title: Use of Ultrasound to Measure Depth of Thoracic Epidural Space Compared With Blind Technique
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Post Operative Trauma
Acute Pain
Keywords: Post operative pain
thoracic epidural
acute pain
Ultrasound scanning of the thoracic spine
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
First posted: 2010-07-30
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having a thoracic epidural catheter for post operative pain

Brief summary: The purpose of the study is to evaluate the use of ultrasound scanning of the thoracic spine to define the point of insertion and the depth of the epidural space compared to the blind technique.

The study hypothesis is the use of Ultrasound will improve the success rate of epidural placement and may also decrease the rate of complications.


Eligibility criteria: Inclusion Criteria:

* Patients 18 years and older having a thoracic epidural catheter
* Both male and female patients.

Exclusion Criteria:

* Pediatric population \< 18 years of age
* Pregnancy
* Prisoners
* Absolute Contraindication to thoracic epidural placement severe scoliosis or deformity,
* Patients with previous spine surgery or hardware implanted at level of epidural placement,
* Anticipated ventilation postoperatively for a period more that 24 hrs
* Lack of patient consent to enroll in the study

Primary outcomes:
measure: The success rate of epidural catheter to control pain
timeFrame: post operative day # 1
Secondary outcomes:
measure: The complication rate from epidural catheter placement.
timeFrame: Immediate complications 24 hrs after
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMass Memorial Medical Center
state: Massachusetts
Study officials:
affiliation: University of Massachusetts, Worcester
name: Issam Khayata, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06362330: Multi-parametric MRI in Patients of Bladder Cancer
Official title: Knowledge-guided Causal Diagnostic Network for the Detection of Muscle-invasive Bladder Cancer With Single T2-weighted Imaging
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Muscle-invasive Bladder Cancer
Artificial Intelligence
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Preoperative multi-parameter magnetic resonance imaging is essential to ascertain whether patients with bladder cancer exhibit muscular invasion, facilitating the selection of appropriate treatment options.

Brief summary: Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive bladder cancer with multiparametric magnetic resonance imaging(MRI).

Detailed description: Patients who underwent bladder MRI were retrospectively collected at three centers between January 2013 and September 2023. The investigators first constructed a nnUNet to segment causal region where muscle-invasive bladder cancer may occur. Subsequently, the investigators explored a causal network based on a modified ResNet3d-18 by striking a fine balance between nnUNet awareness and a self-supervised learning (SSL) model, which steered model to emulate diagnostic acumen of expert in staging muscle-invasive bladder cancer at MRI. Model was trained in center 1, and independently tested in center 1, center 2 and center 3. Ablation test was performed among all 13 Ablation-Test models using either single or multi-parametric MRI. Benefit was tested in six radiologists using vesical imaging-reporting and data system (VI-RADS) versus network-adjusted VI-RADS.

Eligibility criteria: Inclusion Criteria:

* Urothelial carcinoma of the bladder confirmed by final histopathology ②Received a standard contrast-enhanced 3.0T mpMRI before surgery ③All tumors within patients included were resected and received pathologic examination separately

Exclusion Criteria:

①Absence of surgical interventions

②With inadequate image quality or with inadequate pathology for analysis

Primary outcomes:
measure: Muscle-invasive bladder cancer
timeFrame: one month
measure: Non-muscle-invasive bladder cancer
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Yu-Dong Zhang
Study officials:
References:
Clinical trial NCT04507230: COVID-19 Associated Coagulopathy in Egypt
Official title: Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coagulopathy
Keywords: hypercoagulable
COVID-19
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-08-11
Enrollment: 106
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: COVID 19 positive by RT- PCR who are admitted to Assiut University hospitals, Egypt.

Age and sex matched controls

Brief summary: Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.

Detailed description: studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.

Eligibility criteria: Inclusion Criteria:

* patients with COVID 19 positive by RT- PCR

Exclusion Criteria:

* no exclusions

Primary outcomes:
measure: Coagulation screen
timeFrame: 1 month
measure: Thrombophilia screen
timeFrame: 1 month
measure: VWF, FVIII
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University Hospitals
Study officials:
References:
Clinical trial NCT02103530: Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT
Official title: Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Myeloid Leukemia
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2014-04-04
Enrollment: 10
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to investigate whether F-18 FLT PET/CT is useful in early response assessment of induction chemotherapy in acute myeloid leukemia patients.

Detailed description: Assessment of treatment response in AML is very important to determine the next treatment. Standard treatment of AML begins with induction chemotherapy. NCCN guideline recommend to assess the treatment response via bone marrow examination approximately 7-10 days after completion of induction chemotherapy. However, the possibility of sampling error and risks of infection and bleeding are the limitation of bone marrow biopsy.

F-18 fluorodeoxythymidine (FLT) is a radiopharmaceutical for PET, reflecting the proliferation of the cell. F-18 FLT is trapped after phosphorylation by thymidine kinase1, whose expression is increased in replicating cells. There have been several studies that reported F-18 FLT PET could measure health and proliferation of the bone marrow.

The aim of this study is to evaluate if F-18 FLT PET/CT is suitable for early response assessment of induction chemotherapy in acute myeloid leukemia patients.

Eligibility criteria: Inclusion Criteria:

* acute myeloid leukemia
* must receive induction chemotherapy
* 19 years old and over

Exclusion Criteria:

* no standard therapy
* pregnancy

Primary outcomes:
measure: Value of FLT PET/CT in early response assessment of induction chemotherapy in acute myeloid leukemia
timeFrame: 4-6 wks after completion of induction chemotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: St. Vincent's Hospital
state: Gyenggi-do
Study officials:
affiliation: St. Vincent's Hospital, The Catholic University of Korea
name: Woo Hee Choi, MD
role: PRINCIPAL_INVESTIGATOR
References: